Rösler A, Litvin Y, Hage C, Gross J, Cerasi E
J Clin Endocrinol Metab. 1982 Jan;54(1):76-82. doi: 10.1210/jcem-54-1-76.
A family of three generations is described in which six females had hyperthyroidism secondary to chronic overstimulation of the thyroid by pituitary TSH. In the untreated state, their basal levels of T4 ranged between 14-22 microgram/dl, T3 levels ranged from 205-300 ng/dl, T3 resin uptake ranged from 43-61%, TSH ranged from 5-26 microU/ml, and PRL ranged from 33-75 ng/ml. Basal metabolic rate (BMR) was elevated in all patients (+32 to +100%). There was no evidence of pituitary tumor, In spite of elevated circulating thyroid hormones, TRH stimulated TSH and PRL to 25-57 microU/ml and 120-300 ng/ml, respectively. Serum TSH could be suppressed to normal after 1 week of T3 administration (25 microgram three times per day). Concomitantly, serum T3 and T4 levels fell, and the TSH response to TRH became normal. In contrast, T4 (200 microgram/day) administered for 1 and 4 weeks, respectively, to two patients did not suppress the pituitary-thyroidal axis. A long term therapeutic trial was performed in three patients with T3 and a single morning dose of 25-50 microgram. TSH gradually returned to normal, as did thyroid hormone levels and the BMR. The clinical manifestations of hyperthyroidism regressed, and complete remission was achieved after 2-3 months of T3 therapy, which persists to data as long as medication is continued. The inappropriate TSH secretion of our patients appears to be due to partial unresponsiveness of the thyrotroph to thyroid hormone. It is suggested that either the pituitary T4 monodeiodinase is deficient in our patients, resulting in low intracellular T3 levels, or the thyrotroph has reduced sensitivity to T3 and therefore can shut off TSH only when serum T3 is raised to high levels, albeit intermittently.
本文描述了一个三代家族,其中六名女性患有垂体促甲状腺激素(TSH)长期过度刺激甲状腺继发的甲状腺功能亢进症。在未治疗状态下,她们的基础T4水平在14 - 22微克/分升之间,T3水平在205 - 300纳克/分升之间,T3树脂摄取率在43 - 61%之间,TSH在5 - 26微单位/毫升之间,催乳素(PRL)在33 - 75纳克/毫升之间。所有患者的基础代谢率(BMR)均升高(+32%至+100%)。没有垂体肿瘤的证据,尽管循环甲状腺激素升高,但促甲状腺激素释放激素(TRH)分别将TSH和PRL刺激至25 - 57微单位/毫升和120 - 300纳克/毫升。给予T3(每天三次,每次25微克)1周后,血清TSH可被抑制至正常。与此同时,血清T3和T4水平下降,TSH对TRH的反应恢复正常。相比之下,分别给两名患者服用T4(每天200微克)1周和4周,并未抑制垂体 - 甲状腺轴。对三名患者进行了长期治疗试验,每天早晨单次服用25 - 50微克T3。TSH逐渐恢复正常,甲状腺激素水平和BMR也恢复正常。甲状腺功能亢进症的临床表现消退,T3治疗2 - 3个月后实现完全缓解,只要继续用药,这种缓解状态一直持续到目前。我们患者不适当的TSH分泌似乎是由于促甲状腺细胞对甲状腺激素部分无反应。提示要么我们患者的垂体T4单碘酶缺乏,导致细胞内T3水平低,要么促甲状腺细胞对T3的敏感性降低,因此只有当血清T3升高到高水平时(尽管是间歇性的)才能关闭TSH的分泌。